Pharmacokinetic interactions between primaquine and pyronaridine-artesunate in healthy adult Thai subjects.
Pyronaridine-artesunate is a newly introduced artemisinin-based combination treatment which may be deployed together with primaquine. A single-dose, randomized, three-sequence crossover study was conducted in healthy Thai volunteers to characterize potential pharmacokinetic interactions between thes...
| Main Authors: | , , , , , , , , , , , , |
|---|---|
| Format: | Journal article |
| Language: | English |
| Published: |
American Society for Microbiology
2015
|
| _version_ | 1797086205644374016 |
|---|---|
| author | Jittamala, P Pukrittayakamee, S Ashley, E Nosten, F Hanboonkunupakarn, B Lee, S Thana, P Chairat, K Blessborn, D Panapipat, S White, N Day, N Tarning, J |
| author_facet | Jittamala, P Pukrittayakamee, S Ashley, E Nosten, F Hanboonkunupakarn, B Lee, S Thana, P Chairat, K Blessborn, D Panapipat, S White, N Day, N Tarning, J |
| author_sort | Jittamala, P |
| collection | OXFORD |
| description | Pyronaridine-artesunate is a newly introduced artemisinin-based combination treatment which may be deployed together with primaquine. A single-dose, randomized, three-sequence crossover study was conducted in healthy Thai volunteers to characterize potential pharmacokinetic interactions between these drugs. Seventeen healthy adults received a single oral dose of primaquine alone (30 mg base) and were then randomized to receive pyronaridine-artesunate alone (540-180 mg) or pyronaridine-artesunate plus primaquine in combination, with intervening washout periods between all treatments. The pharmacokinetic properties of primaquine, its metabolite carboxyprimaquine, artesunate, its metabolite dihydroartemisinin, and pyronaridine were assessed in 15 subjects using a noncompartmental approach followed by a bioequivalence evaluation. All drugs were well tolerated. The single oral dose of primaquine did not result in any clinically relevant pharmacokinetic alterations to pyronaridine, artesunate, or dihydroartemisinin exposures. There were significantly higher primaquine maximum plasma drug concentrations (geometric mean ratio, 30%; 90% confidence interval [CI], 17% to 46%) and total exposures (15%; 6.4% to 24%) during coadministration with pyronaridine-artesunate than when primaquine was given alone. Pyronaridine, like chloroquine and piperaquine, increases plasma primaquine concentrations. (This study has been registered at ClinicalTrials.gov under registration no. NCT01552330.). |
| first_indexed | 2024-03-07T02:18:47Z |
| format | Journal article |
| id | oxford-uuid:a331d384-179b-428c-852e-043b40f19c1c |
| institution | University of Oxford |
| language | English |
| last_indexed | 2024-03-07T02:18:47Z |
| publishDate | 2015 |
| publisher | American Society for Microbiology |
| record_format | dspace |
| spelling | oxford-uuid:a331d384-179b-428c-852e-043b40f19c1c2022-03-27T02:25:09ZPharmacokinetic interactions between primaquine and pyronaridine-artesunate in healthy adult Thai subjects.Journal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:a331d384-179b-428c-852e-043b40f19c1cEnglishSymplectic Elements at OxfordAmerican Society for Microbiology2015Jittamala, PPukrittayakamee, SAshley, ENosten, FHanboonkunupakarn, BLee, SThana, PChairat, KBlessborn, DPanapipat, SWhite, NDay, NTarning, JPyronaridine-artesunate is a newly introduced artemisinin-based combination treatment which may be deployed together with primaquine. A single-dose, randomized, three-sequence crossover study was conducted in healthy Thai volunteers to characterize potential pharmacokinetic interactions between these drugs. Seventeen healthy adults received a single oral dose of primaquine alone (30 mg base) and were then randomized to receive pyronaridine-artesunate alone (540-180 mg) or pyronaridine-artesunate plus primaquine in combination, with intervening washout periods between all treatments. The pharmacokinetic properties of primaquine, its metabolite carboxyprimaquine, artesunate, its metabolite dihydroartemisinin, and pyronaridine were assessed in 15 subjects using a noncompartmental approach followed by a bioequivalence evaluation. All drugs were well tolerated. The single oral dose of primaquine did not result in any clinically relevant pharmacokinetic alterations to pyronaridine, artesunate, or dihydroartemisinin exposures. There were significantly higher primaquine maximum plasma drug concentrations (geometric mean ratio, 30%; 90% confidence interval [CI], 17% to 46%) and total exposures (15%; 6.4% to 24%) during coadministration with pyronaridine-artesunate than when primaquine was given alone. Pyronaridine, like chloroquine and piperaquine, increases plasma primaquine concentrations. (This study has been registered at ClinicalTrials.gov under registration no. NCT01552330.). |
| spellingShingle | Jittamala, P Pukrittayakamee, S Ashley, E Nosten, F Hanboonkunupakarn, B Lee, S Thana, P Chairat, K Blessborn, D Panapipat, S White, N Day, N Tarning, J Pharmacokinetic interactions between primaquine and pyronaridine-artesunate in healthy adult Thai subjects. |
| title | Pharmacokinetic interactions between primaquine and pyronaridine-artesunate in healthy adult Thai subjects. |
| title_full | Pharmacokinetic interactions between primaquine and pyronaridine-artesunate in healthy adult Thai subjects. |
| title_fullStr | Pharmacokinetic interactions between primaquine and pyronaridine-artesunate in healthy adult Thai subjects. |
| title_full_unstemmed | Pharmacokinetic interactions between primaquine and pyronaridine-artesunate in healthy adult Thai subjects. |
| title_short | Pharmacokinetic interactions between primaquine and pyronaridine-artesunate in healthy adult Thai subjects. |
| title_sort | pharmacokinetic interactions between primaquine and pyronaridine artesunate in healthy adult thai subjects |
| work_keys_str_mv | AT jittamalap pharmacokineticinteractionsbetweenprimaquineandpyronaridineartesunateinhealthyadultthaisubjects AT pukrittayakamees pharmacokineticinteractionsbetweenprimaquineandpyronaridineartesunateinhealthyadultthaisubjects AT ashleye pharmacokineticinteractionsbetweenprimaquineandpyronaridineartesunateinhealthyadultthaisubjects AT nostenf pharmacokineticinteractionsbetweenprimaquineandpyronaridineartesunateinhealthyadultthaisubjects AT hanboonkunupakarnb pharmacokineticinteractionsbetweenprimaquineandpyronaridineartesunateinhealthyadultthaisubjects AT lees pharmacokineticinteractionsbetweenprimaquineandpyronaridineartesunateinhealthyadultthaisubjects AT thanap pharmacokineticinteractionsbetweenprimaquineandpyronaridineartesunateinhealthyadultthaisubjects AT chairatk pharmacokineticinteractionsbetweenprimaquineandpyronaridineartesunateinhealthyadultthaisubjects AT blessbornd pharmacokineticinteractionsbetweenprimaquineandpyronaridineartesunateinhealthyadultthaisubjects AT panapipats pharmacokineticinteractionsbetweenprimaquineandpyronaridineartesunateinhealthyadultthaisubjects AT whiten pharmacokineticinteractionsbetweenprimaquineandpyronaridineartesunateinhealthyadultthaisubjects AT dayn pharmacokineticinteractionsbetweenprimaquineandpyronaridineartesunateinhealthyadultthaisubjects AT tarningj pharmacokineticinteractionsbetweenprimaquineandpyronaridineartesunateinhealthyadultthaisubjects |